A California lawmaker has introduced legislation that would decriminalize psychedelics in the state, the latest bold step in a movement to end America’s war on drugs.
Articles
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
MINDCURE's first line of mushroom-based nootropics now available for sale.
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
MindMed enhances its mental health platform with the acquisition of a machine-learning digital medicine company.
U.S. Psychedelic Drug Legalization: Urgency or Inertia?
Legalized psychedelic drugs are urgently needed to address the Mental Health Crisis. Democrats and Republicans epitomize inertia. The irresistible force meets the immovable object.
Minnesota Marijuana Legalization Bill Approved In First Committee Vote
A bill to legalize marijuana in Minnesota was approved by a House committee on Wednesday—the first of up to a dozen panels that are expected to take up the reform legislation in the weeks to come in advance of a floor vote.
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
Dr. Dan Engle, a noted expert in neurology, will lead MINDCURE's psychedelic drug research on traumatic brain injury
Transatlantic Capital, Inc. Announces Plan To Initiate Early Phases of Cannabis and Psilocybin Production in the Aftermath of Their Most Recent Land Acquisition
PORTLAND, OR / ACCESSWIRE / February 16, 2021 / Transatlantic Capital Inc. (OTC PINK:TACI) announces their plan to begin early stages of mass Cannabis and Psilocybin Mushroom production by early 2021. As mentioned in a previous announcement from October 22nd, 2020, Transatlantic Inc., or "TACI" finalized a land deal that gave them over 250 acres of rural property in Clarendon, Jamaica which will allow them to safely produce and manufacture their medicinal products.
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine closes on CAD$17.25 million, with full over-allotment exercised.
Marijuana Industry Sees Record Jobs Gains In 2020 Despite Pandemic, New Report Shows
The marijuana industry added more than 77,000 jobs over the past year—a 32 percent increase that makes the sector the fastest in job creation compared to any other American industry, according to a new report from the cannabis company Leafly.
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
MINDCURE adds bioinformatics to its drug development platform.
DEA Wants To Know About Applicants’ Hemp And CBD Use, But Only Pre-Legalization
The Drug Enforcement Administration (DEA) wants to know whether its prospective employees or contractors have used hemp or CBD—but only if they used it before December 20, 2018.
Why psychedelics are a more ‘compassionate’ way to treat trauma
THE PAST DECADE has been witness to a renaissance in psychedelics research.
New 5-Year Psychedelics Warrants Offer Exciting Leverage Play
Psychedelic stock warrants have already produced some phenomenal gains for investors. Now a new series of 5-year warrants is trading.
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
MindMed inks a new partnership for drug development and expands its pipeline.
264 Million Reasons Psychedelic Stocks Have More Room to Grow
There is big money to be made from psychedelic stocks and the companies planning to treat depression will be the winners.